Literature DB >> 12901127

Deep venous thrombosis in the medically ill.

Walter Ageno1, Alexander G Turpie.   

Abstract

Epidemiologic data have shown that the risk of venous thromboembolism (VTE) in medical patients is comparable to the risk in surgical patients. Moreover, autopsy studies demonstrated that 75% of all in-hospital deaths for pulmonary embolism occur in nonsurgical patients. Hospitalized medical patients represent a very heterogeneous population. Patients with medical disorders who are at significant risk include those with heart failure, acute respiratory failure, acute infectious diseases, acute rheumatic disorders, inflammatory bowel diseases, and cancer. Recent consensus conferences have produced detailed recommendations for thrombosis prophylaxis in both surgical and medical patients. Both unfractionated heparin and low-molecular-weight heparins (LMWHs) have been shown to be effective when compared with placebo and are recommended in high-risk medical patients. When LMWHs were compared with unfractionated heparin, they were shown to have equivalent efficacy and greater safety than the parent compound. As for surgical patients, routine prophylaxis is still underused in the general medical population.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12901127

Source DB:  PubMed          Journal:  Curr Hematol Rep        ISSN: 1540-3408


  3 in total

1.  The AVAIL ME study: a multinational survey of VTE risk and prophylaxis.

Authors:  Ali T Taher; Joseph Aoun; Pascale Salameh
Journal:  J Thromb Thrombolysis       Date:  2011-01       Impact factor: 2.300

2.  Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol.

Authors:  Alexander Thomas Cohen; Theodore Erich Spiro; Harry Roger Büller; Lloyd Haskell; Dayi Hu; Russell Hull; Alexandre Mebazaa; Geno Merli; Sebastian Schellong; Alex Spyropoulos; Victor Tapson
Journal:  J Thromb Thrombolysis       Date:  2011-05       Impact factor: 2.300

3.  Antithrombotic prophylaxis in the middle East.

Authors:  Samir Arnaout; Hanady R Samaha; Julien Succar; Imad Bou-Akl; Khaled M Musallam; Ali T Taher
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-05-24       Impact factor: 2.576

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.